What's new? Log in Free sign up

Catalyst Pharmaceuticals (CPRX)

Company Profile

Company profile

Ticker

CPRX

Exchange

Website

www.catalystpharma.com

CEO

Mr. Richard John Daly M.B.A.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • AbbVie • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Bausch Health Companies • Eli Lilly and • Bristol-Myers Squibb • Viatris ...

Former names

Catalyst Pharmaceutical Partners, Inc., CATALYST PHARMACEUTICAL PARTNERS, INC., CATALYST PHARMACEUTICALS, INC.

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Catalyst Pharmaceuticals Ireland, Ltd. ...

CPRX stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update

Quarterly report

7 May 25

Annual report to shareholders

Definitive proxy

11 Apr 25

Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

26 Feb 25

Departure of Directors or Certain Officers

Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan

Regulation FD Disclosure

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

Notice of proposed sale of securities

Notice of proposed sale of securities

BlackRock, Inc.

Notice of proposed sale of securities

Carmen Jeffrey Del

Notice of proposed sale of securities

Notice of proposed sale of securities

Financial summary

Financial statements Chart CPRX financial data

Quarter (USD)	Mar 25	Dec 24	Sep 24	Jun 24
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 24	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Institutional ownership, Q4 2024

CPRX institutional ownership history Ownership history

82.6% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	337	312	+8.0%
Opened positions	63	65	-3.1%
Closed positions	38	24	+58.3%
Increased positions	139	96	+44.8%
Reduced positions	91	105	-13.3%

13F shares	Current	Prev Q	Change
Total value	1.97 tn	1.81 tn	+8.9%
Total shares	100.71 mm	101.51 mm	-0.8%
Total puts	11.70 k	51.10 k	-77.1%
Total calls	13.40 k	19.10 k	-29.8%
Total put/call ratio	0.9	2.7	-67.4%

Largest owners	Shares	Value	Change
BlackRock	19.43 mm	$405.40 bn	+2.1%
Vanguard	8.43 mm	$175.96 bn	+4.9%
STT State Street	5.80 mm	$120.97 bn	+2.0%
Deerfield Management	3.13 mm	$65.39 bn	-49.7%
Flynn James E	3.13 mm	$72.66 mm	-49.7%
Dimensional Fund Advisors	3.01 mm	$62.88 bn	-0.2%
Pacer Advisors	2.96 mm	$61.68 bn	+5.4%
GS The Goldman Sachs Group, Inc.	2.80 mm	$58.49 bn	+90.3%
Renaissance Technologies	2.71 mm	$56.48 bn	+7.1%
Geode Capital Management	2.67 mm	$55.64 bn	+0.0%

Largest transactions	Shares	Bought/sold	Change
Deerfield Management	3.13 mm	-3.10 mm	-49.7%
Flynn James E	3.13 mm	-3.10 mm	-49.7%
GS The Goldman Sachs Group, Inc.	2.80 mm	+1.33 mm	+90.3%
BAC Bank of America	1.57 mm	+913.84 k	+139.5%
MQBKY Macquarie Group Limited	682.65 k	+682.65 k	NEW
Marshall Wace	253.64 k	-607.30 k	-70.5%
UBS UBS	722.86 k	+510.01 k	+239.6%
Standard Life Aberdeen	484.67 k	+484.67 k	NEW
Citadel Advisors	436.47 k	+411.23 k	+1629.4%
BlackRock	19.43 mm	+407.64 k	+2.1%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

CPRX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
14 May 25	Gary Ingenito	Common stock, par value $0.001 per share	Sell	Dispose S	No	No	23.63	44,000	1.04 mm	68,873
14 May 25	Gary Ingenito	Common stock, par value $0.001 per share	Option exercise	Acquire M	No	No	4.64	44,000	204.16 k	112,873
14 May 25	Gary Ingenito	Options to purchase common stock Common Stock	Option exercise	Dispose M	No	No	4.64	44,000	204.16 k	546,282
13 May 25	Gary Ingenito	Common stock, par value $0.001 per share	Sell	Dispose S	No	No	23.68	200,000	4.74 mm	68,873
13 May 25	Gary Ingenito	Common stock, par value $0.001 per share	Option exercise	Acquire M	No	No	3.42	200,000	684.00 k	268,873
13 May 25	Gary Ingenito	Options to purchase common stock Common Stock	Option exercise	Dispose M	No	No	3.42	200,000	684.00 k	590,282
6 Mar 25	Gary Ingenito	Common stock, par value $0.001 per share	Sell	Dispose S	No	No	21.67	180,096	3.90 mm	68,873
6 Mar 25	Gary Ingenito	Common stock, par value $0.001 per share	Option exercise	Acquire M	No	No	2.24	180,096	403.42 k	248,969
6 Mar 25	Gary Ingenito	Options to purchase common stock Common Stock	Option exercise	Dispose M	No	No	2.24	180,096	403.42 k	790,282
5 Mar 25	Gary Ingenito	Common stock, par value $0.001 per share	Sell	Dispose S	No	No	22.09	44,904	991.93 k	68,873

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Catalyst Pharmaceuticals Affirms FY2025 Sales Guidance of $545.00M-$565.00M vs $557.24M Est

Catalyst Pharmaceuticals (NASDAQ:CPRX) affirms FY2025 sales outlook from $545.00 million-$565.00 million to $545.00 million-$565.00 million vs $557.24 million estimate.

Catalyst Pharmaceuticals Q1 Adj. EPS $0.68 Beats $0.53 Estimate, Sales $141.42M Beat $130.86M Estimate

Catalyst Pharmaceuticals (NASDAQ:CPRX) reported quarterly earnings of $0.68 per share which beat the analyst consensus estimate of $0.53 by 28.3 percent. This is a 78.95 percent increase over earnings of $0.38 per share

Earnings Scheduled For May 7, 2025

Celsius, Lucid And Signet Are Among Top 10 Mid-Cap Gainers Last Week (Mar 17-Mar 21): Are The Others In Your Portfolio?

Baird Maintains Outperform on Catalyst Pharmaceuticals, Raises Price Target to $32

Press releases

From Benzinga Pro

Catalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025

CORAL GABLES, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and

Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025

CORAL GABLES, Fla., April 22, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,

Catalyst Pharmaceuticals Announces Health Canada's Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals

CORAL GABLES, Fla., April 08, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,

New Drug Submission for AGAMREE® (vamorolone) Accepted for Priority Review by Health Canada for the Treatment of Duchenne Muscular Dystrophy

Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.